ArticleJournal of obstetrics and gynaecology of India2025
Maternal and Fetal Outcomes in Gestational Diabetes Mellitus Treated with Metformin with or Without Insulin.
Article in Journal of obstetrics and gynaecology of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational Diabetes Mellitus (GDM) is linked with a multitude of adverse perinatal outcomes. There is a want for standard guidelines regarding the usage of Metformin in GDM. We aimed to study the perinatal outcomes in women diagnosed with GDM treated primarily with Metformin with or without Insulin. Methods: We conducted a randomized controlled pilot study. with a total of 75 women, divided into three groups: GDM treated with Metformin with or without Insulin (Group M), GDM on Insulin alone (Group I), and healthy pregnant women as controls (Group H), with 25 subjects in each group. At delivery, fetal and maternal outcomes were documented. Results: The mean age in groups M, I and H were 27.4, 26.2, and 27.3 years respectively. The baseline mean HOMA-IR were 3.9 and 4.1 for Group M and Group I, respectively ( Conclusion: The study revealed identical maternal and fetal outcomes in women treated with Metformin as the primary drug compared to conventional treatment with Insulin in GDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.